Compare ADUS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADUS | XNCR |
|---|---|---|
| Founded | 1979 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2009 | 2013 |
| Metric | ADUS | XNCR |
|---|---|---|
| Price | $119.33 | $26.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $133.78 | $22.33 |
| AVG Volume (30 Days) | 165.6K | ★ 1.3M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.40 | ★ 65.36 |
| EPS | ★ 2.85 | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $4.70 | $4.80 |
| P/E Ratio | $41.46 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $87.95 | $8.29 |
| 52 Week High | $124.44 | $30.61 |
| Indicator | ADUS | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 57.44 |
| Support Level | $114.12 | $11.20 |
| Resistance Level | $121.73 | $30.61 |
| Average True Range (ATR) | 2.80 | 1.71 |
| MACD | -0.62 | -0.33 |
| Stochastic Oscillator | 55.78 | 45.14 |
Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.